13:03:11 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaSpotlight
SektorMaterial
IndustriForskning & Utveckling
Nanologica är verksamma inom nanoteknik. Idag innehas störst affärsinriktning mot sektorerna Drug Delivery och Kromatografi, vilket innefattar utveckling av läkemedelsadministration samt av teknik som används för separation och rening av produkter. Forskningen har utförts i samarbete med Stockholms Universitet och Ångströmslaboratorierna vid Uppsala Universitet. Bolaget grundades 2004 och har sitt huvudkontor i Södertälje.

Kalender

2021-02-19 Bokslutskommuniké 2020
2020-10-30 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-29 Ordinarie utdelning NICA 0.00 SEK
2020-05-28 Årsstämma 2020
2020-02-26 Extra Bolagsstämma 2020
2020-02-24 Kvartalsrapport 2020-Q1
2020-02-07 Bokslutskommuniké 2019
2019-10-25 Kvartalsrapport 2019-Q3
2019-08-27 Kvartalsrapport 2019-Q2
2019-05-31 Ordinarie utdelning NICA 0.00 SEK
2019-05-29 Årsstämma 2019
2019-05-10 Kvartalsrapport 2019-Q1
2019-02-15 Bokslutskommuniké 2018
2018-11-23 Kvartalsrapport 2018-Q3
2018-08-23 Kvartalsrapport 2018-Q2
2018-06-01 Ordinarie utdelning NICA 0.00 SEK
2018-05-31 Årsstämma 2018
2018-04-25 Kvartalsrapport 2018-Q1
2018-02-23 Bokslutskommuniké 2017
2017-11-23 Kvartalsrapport 2017-Q3
2017-08-25 Kvartalsrapport 2017-Q2
2017-06-02 Ordinarie utdelning NICA 0.00 SEK
2017-06-01 Årsstämma 2017
2017-05-19 Kvartalsrapport 2017-Q1
2017-02-23 Bokslutskommuniké 2016
2016-11-17 Kvartalsrapport 2016-Q3
2016-09-12 Extra Bolagsstämma 2016
2016-08-26 Kvartalsrapport 2016-Q2
2016-06-01 Ordinarie utdelning NICA 0.00 SEK
2016-05-31 Årsstämma 2016
2016-05-20 Kvartalsrapport 2016-Q1
2016-02-19 Bokslutskommuniké 2015
2015-11-26 Kvartalsrapport 2015-Q3
2020-04-16 09:24:09

Nanologica will participate in the virtual partnering event Partnering Against COVID-19 on May 4 - 6.

The aim of the event is to support the fight against COVID-19 and to accelerate global collaboration.

Participating parties will consist of organizations working with solutions for COVID-19 testing, treatment and prevention.

"In these difficult times, we are excited to take part of such an important event. Our inhalation technology is still in early stages but has the potential to be an interesting platform for formulating drugs targeting COVID-19, as well as other diseases affecting the lungs. If we could in any way contribute to the fight against COVID-19, it would be a great achievement", says Andreas Bhagwani, CEO Nanologica.

For technical information on Nanologica's drug delivery platform, please contact:

Kia Bengtsson, Director Drug Development Nanologica

Ph: +46 70 144 36 30 or e-mail: kia.bengtsson@nanologica.com
 

Adam Feiler, CTO Nanologica

Ph: +46 72 353 66 30 or e-mail adam.feiler@nanologica.com

For further information, please contact:

Johanna Johansson, IR Nanologica
Ph: +46 72 211 21 90 or e-mail: johanna.johansson@nanologica.com

About Nanologica AB (publ)
Nanologica was founded in 2004 and is a nanotechnology company developing nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size and type of porosity of silica particles. This knowledge is applied within drug development and chromatography (a separation technique used in drug development and drug production). The company's mission is to contribute to better and cheaper treatments for patients worldwide through the technology platform NLAB Silica™. Nanologica's stock (NICA) is listed on Spotlight Stock Market. For further information, please visit www.nanologica.com.